rce.ai

rce.ai is an innovative artificial intelligence (AI) based medical technology company, dedicated to early heart attack detection. The company has revolutionized the monitoring of cardiac injury by introducing a non-invasive infrared-based wearable. Their proprietary transdermal approach, enhanced with deep learning techniques, analyzes and associates unique optical signatures with cardiac conditions in real-time. This AI coupled transdermal approach enables the potential application of their platform technology in various emergency care settings and remote monitoring applications. As of 2018, they are engaged in clinical studies to optimize their product for clinical use. It’s important to note that rce.ai’s technology is not yet FDA approved and is not available for sale in the US. The latest investment for the company was a Non Equity Assistance investment at 14 July 2023 by The Cedars-Sinai Accelerator. With a focus on Health Care, the company is headquartered in the United States.